Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma

被引:67
作者
Bedikian, Agop Y. [1 ]
Johnson, Marcella M. [1 ]
Warneke, Carla L. [1 ]
Papadopoulos, Nicholas E. [1 ]
Kim, Kevin [1 ]
Hwu, Wen-Jen [1 ]
Mclntyre, Susan [1 ]
Hwu, Patrick [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA
关键词
melanoma; chemotherapy; biochemotherapy; interleukin-2; survival;
D O I
10.1080/07357900802027073
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This retrospective analysis aimed to identify the prognostic factors that influenced long-term survival of patients with metastatic melanoma. The medical records for 616 chemo-naive patients who were treated with systemic therapy on eight phase II/III clinical trials were reviewed. Clinical characteristics, disease stage, metastatic sites, baseline serum albumin, LDH, and response to treatment were compared between the treatment groups and significant prognostic factors were identified. Cox proportional-hazards regression analysis identified treatment with biochemotherapy, younger age, normal baseline serum albumin and LDH levels, ECOG P.S. < 2 and absence of visceral metastasis as favorable prognostic factors for long-term survival.
引用
收藏
页码:624 / 633
页数:10
相关论文
共 57 条
  • [1] AHMANN DL, 1989, CANCER, V63, P224, DOI 10.1002/1097-0142(19890115)63:2<224::AID-CNCR2820630203>3.0.CO
  • [2] 2-I
  • [3] Allen IE, 1998, CANC THER, V1, P168
  • [4] Anderson C M, 1995, Oncology (Williston Park), V9, P1149
  • [5] Anderson C. M., 1995, ONCOLOGY HUNTINGT, V9, P1167
  • [6] Anderson C. M., 1995, ONCOLOGY HUNTINGT, V9, P1163
  • [7] [Anonymous], 1979, HDB REP RES CANC TRE
  • [8] MULTIINSTITUTIONAL PHASE-II TRIAL OF INTENSIVE COMBINATION CHEMOIMMUNOTHERAPY FOR METASTATIC MELANOMA
    ATKINS, MB
    OBOYLE, KR
    SOSMAN, JA
    WEISS, GR
    MARGOLIN, KA
    ERNEST, ML
    KAPPLER, K
    MIER, JW
    SPARANO, JA
    FISHER, RI
    ECKARDT, JR
    PEREIRA, C
    ARONSON, FR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) : 1553 - 1560
  • [9] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
    Atkins, MB
    Lotze, MT
    Dutcher, JP
    Fisher, RI
    Weiss, G
    Margolin, K
    Abrams, J
    Sznol, M
    Parkinson, D
    Hawkins, M
    Paradise, C
    Kunkel, L
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2105 - 2116
  • [10] ATKINS MB, 2003, J CLIN ONCOL, V22, P70